Apellis Has New Hope for Pegcetacoplan With Longer-Term Data

18-Month Results Could Vindicate Geographic Atrophy Program

One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.

Eye — Apellis announced longer-term data for pegcetacoplan in geographic atrophy • Source: Shutterstock

Apellis Pharmaceuticals, Inc. bolstered its chances of success for its intravitreal pegcetacoplan in geographic atrophy with Phase III follow-up data that vindicated a study previously viewed as a failure.

Apellis said on 16 March that in longer-term data from the Phase III DERBY and OAKS studies, pegcetacoplan had continued...